base-metals-investing Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
base-metals-investing Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
base-metals-investing Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
base-metals-investing Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
base-metals-investing Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
base-metals-investing Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
base-metals-investing Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
base-metals-investing Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
Intercontinental Exchange CFO Warren Gardiner to Present at the UBS Financial Services Conference on February 9
